Effect of NK cell therapy in COVID-19

Phase 1

Recruiting

Conditions: Condition 1: COVID-19. Condition 2: COVID-19. Condition 3: Viral pneumonia.
COVID-19, virus identified
COVID-19, virus not identified
Other viral pneumonia
U07.1
U07.2
J12.8

Registration Number: IRCT20200417047113N1

Lead Sponsor: Middle East Gene Therapy corporation

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 70

Inclusion Criteria

All COVID-19 patients confirmed by CT scan with possitive RT-PCR

Exclusion Criteria

Pregnancy or breastfeeding
Known HIV, HBV or HCV infection
Patients with malignant tumor, other serious systemic diseases and psychosis
Diabetic patients
Patients who are participating in other clinical trials

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fever. Timepoint: Days 1, 3, 7, 14, and 28. Method of measurement: Thermometer.;Number of breathes per minute. Timepoint: Days 1, 3, 7, 14, and 28 after cell injection. Method of measurement: Records of the number of breaths in a minute by Nurse in 3 consecutive minutes.;Pulmonary volume. Timepoint: Days 7 and 14. Method of measurement: Spirometer.;Pulmonary capacity. Timepoint: Days 7 and 14. Method of measurement: Spirometer.;Airway resistance. Timepoint: Days 7 and 14. Method of measurement: Spirometer.;Lung elasticity. Timepoint: Days 7 and 14. Method of measurement: Spirometer.;Chest pressure. Timepoint: Days 7 and 14. Method of measurement: Spirometer.;Cough. Timepoint: Days 1, 3, 7, 14, and 28 after cell injection. Method of measurement: Records in questionnaire by nurse according to defined qualitative criteria.;Skin disorders. Timepoint: Days 1, 3, 7, 14, and 28. Method of measurement: Records in questionnaire by nurse according to defined qualitative criteria.

Secondary Outcome Measures